U.S. Supreme Court News:On June 13, 2013, the U.S. Supreme Court delivered its much-anticipated decision in the case of the Association of Molecular Pathology v. Myriad Genetics, concerning the patent eligibility of claims to “isolated” genomic DNA sequences and cDNA sequences.  The Court found Myriad’s claims to isolated genomic DNA sequences to be ineligible for patenting but claims to cDNA sequences to be patent-eligible.  A copy of the opinion may be downloaded here.